Publications

5803 Results

New prognostic score incorporating MTV predicts treatment failure in advanced Hodgkin Lymphoma

Authors
S Barrington;A Kirkwood;L Pike;C Guezennec;H Li;M Leblanc;D Poon;M Knopp;L Clifton-Hadley;C Laubach;H Schoder;JW Friedberg;P Johnson
Journal / Conference
International Conference on Malignant Lymphoma 2021 (tentative June 2021), oral
Year
2021
Research Committee(s)
Lymphoma
Study Number(s)
S0816

Cognitive Function And Quality Of Life In Long Term Survivors Of RTOG 9402

Authors
L Donavan;M Won;J Cairncross;F Iwamoto;J Buckner;K Fink;J-P Bahary;A Hartford;L Souhami;T Nguyen;T Cescon;M Mishra;I Barani;A Pu;W Roa;J Huang;M Polley;M Mehta
Journal / Conference
Society for Neuroncology (SNO) Annual Meeting (November 18-21, 2021, Boston), oral
Year
2021
Research Committee(s)
Brain
Study Number(s)
SWOG-9402

Treatment-specific gene regulatory pathways in colorectal cancer patients

Authors
A Yazdani;H-J Lenz;X Qu;M Bertagnolli;A Venook;F Innocenti
Journal / Conference
American Society of Human Genetics (ASHG) Annual Meeting (October 18-22), poster, PrgmNr 2776
Year
2021
Research Committee(s)
Gastrointestinal
Study Number(s)
CTSU/C80405

Distant-Disease Free Interval in participants (pts) with 1-3 positive lymph nodes (LN), hormone receptor-positive (HR+) and HER2-negative (HER2-) breast cancer (BC) with recurrence score (RS) < 25 randomized to endocrine therapy (ET) +/- chemotherapy (CT): SWOG S1007 (RxPONDER)

Authors
K Kalinsky;W Barlow;J Gralow;F Meric-Bernstam;K Albain;D Hayes;N Lin;E Perez;L Goldstein;S Chia;S Dhesy-Thind;P Rastogi;E Alba;S Delaloge;M Martin;C Kelly;M Ruiz Borrego;M Gil-Gil;C Arce-Salinas;E Brain;E Lee;J-Y Pierga;B Bermejo;M Ramos Vazquez;K Jung;J-M Ferrero;A Schott;S Shak;P Sharma;D Lew;J Miao;D Tripathy;L Pusztai;G Hortobagyi
Journal / Conference
San Antonio Breast Cancer Symposium (Dec 7-10, 2021, San Antonio, TX), oral slide presentation, #GS2-07
Year
2021
Research Committee(s)
Breast
Study Number(s)
S1007

Evaluation of the predicted sensitivity to endocrine therapy (SET2,3 index) and the 21-gene Recurrence Score in node-positive postmenopausal breast cancer: results from an analysis in the SWOG S8814 trial

Authors
C Speers;WF Symmans;W Barlow;A Trevarton;S The;L Du;J Rae;S Shak;R Baehner;P Sharma;L Pusztai;G Hortobagyi;D Hayes;K Albain;A Godwin;A Thompson
Journal / Conference
San Antonio Breast Cancer Symposium (Dec 7-10, 2021, San Antonio, TX), spotlight poster discussion, #PD9-06
Year
2021
Research Committee(s)
Breast
Study Number(s)
SWOG-8814

SWOG S1931 (PROBE trial): Phase III randomized trial of Immune checkpoint inhibitor (ICI) combination regimen with or without Cytoreductive Nephrectomy (CN) in Advanced Renal Cancer

Authors
U Vaishampayan;C Tangen;A Tripathi;B Shuch;S Pal;P Barata;A Tan;P Zuckerman;E Mayerson;P Lara;N Agarwal;N Vogelzang;I Thompson;H Kim
Journal / Conference
Society of Urologic Oncology (Dec 1-3, 2021, Orlando, FL), poster
Year
2021
Research Committee(s)
Genitourinary
Study Number(s)
S1931

Enrollment Characteristics and Outcomes of Hispanic and Black AYA ALL Patients Enrolled on a U.S. Intergroup Clinical Trial: A Comparison of the CALGB 10403 (Alliance) Cohort with U.S. Population-Level Data

Authors
L Muffly;J Yin;S Jacobson;A Advani;S Luger;M Tallman;M Litzow;R Larson;T Keegan;W Stock
Journal / Conference
American Society of Hematology (Dec 11-14, 2021, Atlanta, GA), oral, #337
Year
2021
Research Committee(s)
Leukemia
Study Number(s)
C10403

A041702: A Randomized Phase III Study of Ibrutinib Plus Obinutuzumab Versus Ibrutinib Plus Venetoclax and Obinutuzumab in Untreated Older Patients (= 70 Years of Age) with Chronic Lymphocytic Leukemia (CLL)

Authors
J Woyach;A Ruppert;G Perez;A Booth;D Feldman;E Dib;A Jatoi;J Le-Rademacher;N Heerema;G Lozanski;R Little;B Hill;W Ding;R Stone;S Mandrekar;J Byrd
Journal / Conference
American Society of Hematology (Dec 11-14, 2021, Atlanta, GA), poster, #3728
Year
2021
Research Committee(s)
Leukemia

Long term results of A041202 show continued advantage of ibrutinib-based regimens compared with bendamustine plus rituximab chemoimmunotherapy

Authors
J Woyach;A Ruppert;N Heerema;W Zhao;A Booth;W Ding;N Bartlett;D Brander;P Barr;K Rogers;S Parikh;S Coutre;A Hurria;G Lozanski;S Nattam;R Larson;H Erba;M Litzow;C Owen;J Atkins;J Abramson;R Little;S Smith;R Stone;S Mandrekar;J Byrd
Journal / Conference
American Society of Hematology (Dec 11-14, 2021, Atlanta, GA), oral, #639
Year
2021
Research Committee(s)
Leukemia
Study Number(s)
CTSU/A041202

Extranodal presentation in limited stage DLBCL as a prognostic marker in three sequential SWOG trials S0014, S0313 and S1001 (NCT00005089, NCT00070018, NCT01359592)

Authors
D Stephens;H Li;L Constine;T Fitzgerald;J Leonard;Kahl;J Song;M LeBlanc;S Smith;JW Friedberg;D Persky
Journal / Conference
American Society of Hematology (Dec 11-14, 2021, Atlanta, GA), poster presentation, #1423
Year
2021
Research Committee(s)
Lymphoma
Study Number(s)
S0014, S0313, S1001